Put simply, to develop medicines for all, we must conduct research for all. Clinical trials must represent the broad diversity of patients we serve and enable equitable access.
A special feature in the April Clinical Researcher puts a spotlight on how the life sciences sector has been undergoing an immense transformation, driven by the adoption of artificial intelligence (AI), machine learning, and natural language processing, and by the exploitation of “big data” sources in new and powerful ways.
Identifying key obstacles is a vital step towards closing gaps in clinical research professional workforce development and diversity, equity and inclusion at academic medical centers.
Clinical trials are increasingly using longitudinal evidence generation, where repeated measurements are taken over time from the same set of patients. This is leading to changes in expectations of how research sites carry out trials.
Understand the Process and Manage the Consequences Many changes were made to the U.S. Food and Drug Administration’s (FDA's) requirements for clinical research during the COVID-19 pandemic, including adoption of […]